Necrostatin-1
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Necrostatin-1
Description:
Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC50=182 nM) . Necrostatin-1 is also an IDO inhibitor[1].Product Name Alternative:
Nec-1UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
Autophagy; Ferroptosis; Indoleamine 2,3-Dioxygenase (IDO) ; Necroptosis; RIP kinaseType:
Reference compoundRelated Pathways:
Apoptosis; Autophagy; Metabolic Enzyme/ProteaseApplications:
Cancer-Kinase/proteaseField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/Necrostatin-1.htmlPurity:
99.89Solubility:
DMSO : 125 mg/mL (ultrasonic)Smiles:
O=C(C(CC1=CNC2=C1C=CC=C2)N3)N(C)C3=SMolecular Formula:
C13H13N3OSMolecular Weight:
259.33Precautions:
H302, H315, H319, H335References & Citations:
[1]Degterev A, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005 Jul;1 (2) :112-9.|[2]Linkermann A, et al. The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013 Oct;24 (10) :1545-57.|[3]Huang C, et al. Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS One. 2013 Jun 28;8 (6) :e66326.|[4]Feyen D, et al. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res. 2013 Jul 1;99 (1) :83-91.|[5]Zhou K, et al. RIP1-RIP3-DRP1 pathway regulates NLRP3 inflammasome activation following subarachnoid hemorrhage. Exp Neurol. 2017 Sep;295:116-124.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
No Development ReportedCAS Number:
[4311-88-0]
